Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Relmacabtagene autoleucel by Bristol-Myers Squibb for Systemic Sclerosis (Scleroderma): Likelihood of Approval
Relmacabtagene autoleucel is under clinical development by Bristol-Myers Squibb and currently in Phase I for Systemic Sclerosis (Scleroderma). According to...